Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies

 Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies

Gilead and Jounce’s JTX-1811 Receives US FDA’s IND Clearance for Cancer Immunotherapies

Shots:

  • Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally, it is eligible to receive upto $660M in future clinical, regulatory and commercial milestone payments along with royalties based upon the w/w sales after receiving a $25M milestone
  • Jounce led the development of JTX-1811 through IND clearance, and thereafter Gilead has exclusive rights to develop and commercialize the program
  • JTX-1811 is a mAb, targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Real Money- The Street

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post